RESEARCHER PROFILE

Marc Peeters

← Back to University of Antwerp

M

University of Antwerp

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsCancer Genomics and DiagnosticsGenetic factors in colorectal cancerLung Cancer Treatments and Mutations

Marc Peeters works in Colorectal Cancer Treatments and Studies, Colorectal Cancer Surgical Treatments, Cancer Genomics and Diagnostics, Genetic factors in colorectal cancer, Lung Cancer Treatments and Mutations. Recorded institutional associations include University of Antwerp.

1,272Publications
40,910Citations
92H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

    2008 · 3,208 citations

  2. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

    2007 · 1,981 citations

  3. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    2015 · 1,422 citations

  4. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    2011 · 1,058 citations

  5. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

    2010 · 1,007 citations

  6. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

    2017 · 838 citations

  7. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

    2007 · 827 citations

  8. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum

    1991 · 759 citations

  9. Controlled trial of metronidazole treatment for prevention of crohn's recurrence after ileal resection

    1995 · 745 citations

  10. Utility of Positron Emission Tomography for the Staging of Patients With Potentially Operable Esophageal Carcinoma

    2000 · 571 citations

  11. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

    2009 · 532 citations

  12. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

    2014 · 473 citations

  13. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis

    1999 · 462 citations

  14. Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy

    2010 · 408 citations

  15. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

    2017 · 403 citations

  16. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

    2001 · 393 citations

  17. Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

    2009 · 368 citations

  18. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

    2016 · 354 citations

  19. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease

    2001 · 344 citations

  20. The value of serologic markers in indeterminate colitis: A prospective follow-up study

    2002 · 333 citations

  21. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

    2005 · 306 citations

  22. Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays

    2012 · 300 citations

  23. Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study

    2010 · 294 citations

  24. Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics

    1996 · 293 citations

  25. Histopathologic Validation of Lymph Node Staging With FDG-PET Scan in Cancer of the Esophagus and Gastroesophageal Junction

    2000 · 267 citations

← Return to the university profile